⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4374658 | 0.76 | — | — | |
| SCHEMBL4785534 | 0.67 | — | — | |
| SCHEMBL6406378 | 0.67 | — | — | |
| SCHEMBL4832607 | 0.64 | — | — | |
| SCHEMBL11525533 | 0.64 | — | — | |
| SCHEMBL3174810 | 0.63 | HTR6 (0.31) | — | |
| SCHEMBL2331298 | 0.62 | — | — | |
| SCHEMBL7877974 | 0.61 | — | — | |
| SCHEMBL7554647 | 0.61 | — | — | |
| SCHEMBL11432005 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5958904-A | Phosphonomethyl-imidazo 1,2-A! pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury | G.D. SEARLE & CO. (US) | 1999-09-28 | — | — | US | claimed |
| US-5482933-A | ANOXIA, ISCHEMIA | G. D. SEARLE & CO. (US) | 1996-01-09 | — | — | US | claimed |
| US-5302586-A | Antiischemic and -hypoxia agents, particularly after a stroke, cardiac arrest, hypoglycemia or perinatal asphxia | G. D. SEARLE & CO. (US) | 1994-04-12 | — | — | US | claimed |
| US-8178496-B2 | Photoreactive regulator of glutamate receptor function and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011063164-A2 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | STEADY SLEEP RX CO., INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20090181454-A1 | PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF | ENERGY, UNITED STATE DEPARTMENT OF | 2009-07-16 | — | — | US | disclosed |
| US-7247610-B2 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI | 2007-07-24 | — | — | US | disclosed |
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1586321-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2005-10-19 | — | — | EP | disclosed |
| US-20050054619-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | disclosed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | disclosed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | disclosed |
| US-5958904-A | Phosphonomethyl-imidazo 1,2-A! pyrimidine-2-carboxylic acid compounds for treatment of neurotoxic injury | G.D. SEARLE & CO. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5482933-A | ANOXIA, ISCHEMIA | G. D. SEARLE & CO. (US) | 1996-01-09 | — | — | US | disclosed |
| US-5302586-A | Antiischemic and -hypoxia agents, particularly after a stroke, cardiac arrest, hypoglycemia or perinatal asphxia | G. D. SEARLE & CO. (US) | 1994-04-12 | — | — | US | disclosed |
| US-5252563-A | 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury | G. D. SEARLE & COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| US-5252563-A | 5,6,7,8-tetrahydro-imidazo[1,2-a]pyrimidine compounds for treatment of neurotoxic injury | G. D. SEARLE & COMPANY (US) | 1993-10-12 | — | — | US | disclosed |